Bone Biologics (BBLG) Cash from Financing Activities (2012 - 2025)

Bone Biologics (BBLG) has 12 years of Cash from Financing Activities data on file, last reported at $4.4 million in Q2 2025.

• Cash from Financing Activities for Q2 2025 came in at $4.4 million, up 1455683.28% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.7 million (up 6.26% YoY), and the FY2025 annual result was $4.7 million, up 6.26% from the prior year.
• Cash from Financing Activities grew to $4.4 million in Q2 2025 per BBLG's latest filing, from $347549.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $6.9 million in Q4 2021 and troughed at $299.0 in Q2 2024.
• A 4-year average of $1.6 million and a median of $591998.0 in 2023 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 1455683.28% in 2025 and fell as far as 76.9% in 2025.
• A 4-year view of Cash from Financing Activities shows it stood at $6.9 million in 2021, then tumbled by 91.37% to $591998.0 in 2023, then jumped by 87.87% to $1.1 million in 2024, then soared by 291.37% to $4.4 million in 2025.
• Business Quant data shows BBLG's Cash from Financing Activities at $4.4 million in Q2 2025, $347549.0 in Q1 2025, and $1.1 million in Q4 2024.